Participants will be randomized (3:1) to receive MK-1986 ≤200 mg daily dose (~4 mg/kg to ~6 mg/kg), IV and/or oral suspension for 6 or 10 days, or comparator IV and/or oral per local standard of care for 10 or 14 days. The switch from IV to oral administration can be made at any time based on 1) no worsening of the primary skin lesion, 2) last temperature <37.7 °C, and 3) primary ABSSSI site has not worsened and at least 1 site has improved from Baseline. The potential 4-day treatment extension will be based on 1) ≥40% reduction in lesion size, 2) reduction in pain, and 3) no new signs and symptoms and no complications attributable to ABSSSI compared with Baseline.